 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Xeris Pharmaceuticals, Inc. NASDAQ: XERS and Strongbridge Biopharma plc is fair to Xeris shareholders. Upon closing, Xeris shareholders will exchange each share of Xerix common stock they own for 1 share of the combined company. Current Xeris shareholders are expected to own approximately 60 of the combined company. Halper Sadeh encourages Xeris shareholders to click here to 